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ABSTRACT
Aims:  Prescribing  nicotine  replacement  therapy  (NRT)  or  bupropion  for  smoking 
cessation  is  of  considerable  importance  to  public  health  but  little  is  known  about 
prescribing practices. This paper examines GPs’ prescribing patterns in Britain where 
these drugs are reimbursed. It also explores what underlies differences between them 
in prescribing behaviour. The results have implications for other healthcare systems 
considering introducing reimbursement.
Design,  participants  and  setting:  Postal  survey  conducted  in  2002  of  a  random 
sample of 1088 GPs in England and Wales of whom 642 (59%) responded.
Measures: Number of requests GPs reported having received from patients for NRT 
and bupropion over the past month, the number of prescriptions they reported issuing 
and ratings of attitudes to these medications. 
Findings: GPs reported receiving an average of 4.3 requests for NRT and 1.9 for 
bupropion in the previous month. They reported issuing 3.5 prescriptions for NRT and 
1.2 for bupropion. Almost all GPs accepted that NRT (95%) and bupropion (97%) 
should be reimbursable on National Health Service (NHS) prescription. However, a 
significant minority of those who received requests for prescriptions did not issue any 
(8% for NRT and 26% for bupropion). This was related to whether they thought these 
products should be available on NHS prescription for both NRT (OR [odds ratio] for any prescribing versus none = 0.55, p<.03) and bupropion (OR = 0.66, p<.05) which 
in turn was related to beliefs about whether smokers should have to pay for treatment 
themselves, the cost-effectiveness of NRT/bupropion and the low priority they would 
give NRT/bupropion in the drug budget. For bupropion, concern about side effects 
independently predicted not prescribing (OR = 1.46, p <.03). 
Conclusion: In the British healthcare system which has a well-established system for 
technology  assessment  and  clear  professionally  endorsed  guidelines,  a  significant 
minority  of  GPs  decline  all  patient  requests  for  stop  smoking  medicines  and  this 
appears to relate to broad attitudes to smoking cessation including value judgements 
about who should bear the cost.
Key  words:  nicotine  replacement  therapy  (NRT),  bupropion,  general  practitioners 
(GPs), smoking cessationIntroduction
Stopping smoking improves health and reduces the risk of premature death [1], but is 
made particularly difficult by dependence on nicotine [2]. Both NRT [3] and bupropion 
[4, 5] are effective aids to smoking cessation and are now available on National Health 
Service (NHS) prescription in the UK (making them reimbursable). The National Institute 
of Clinical Excellence (NICE) has concluded that they are among the most cost-effective 
life saving interventions available to the health care system today [6]. National smoking 
cessation guidelines recommend that GPs should provide accurate information on NRT 
and bupropion and prescribe these drugs to smokers motivated to stop and seeking help to 
do so [7]. Following the availability of NRT and bupropion on NHS prescription, since 
May 2001 and July 2000 respectively, the drug budgets of GPs were increased, although 
this  money  was  added  to  the  general  medicines  budget  and  not  restricted  to 
pharmacotherapy  for  smoking  cessation.  The  general  medicines  budget  is  money 
allocated annually by the government to general practices to cover the estimated cost of 
all medicines; these finite resources do not commonly result in patients being denied vital 
medicines, but GPs may have to prioritise their prescribing of non-vital medications.
The  extent  of  demand  for  these  medications  and  GP  prescribing  patterns  are  not 
known. Neither is it known to what extent GPs believe that it is appropriate for these 
medications to be part of their treatment armamentarium. We conducted research on 
this latter issue in 2000 and found only limited support for NRT being placed on NHS 
prescription  [8].  However,  the  situation  has  changed  substantially  since  then  with 
updated national smoking cessation guidelines and the medications having actually 
been  placed  on  the  list  of  reimbursable  medications.  The  issue  is  of  considerable 
importance  both  because  of  the  potential  for  these  medications  to  save  many thousands of lives and because they may still occupy something of a grey area in 
thinking about what should be considered a legitimate use of NHS funds. The results 
should be of interest to other health systems that are considering or will consider 
reimbursing smoking cessation medications.
Methods
A postal survey was conducted of a random sample of 1088 GPs in England and 
Wales conducted between January and March 2002. There were 466 responses to the 
initial mailing; a second mailing was sent to the non-responders four weeks later, 
yielding  a  further  176  responses.  In  15  cases  the  questionnaire  was  returned 
uncompleted because the GP had moved away or was no longer practising. The 642 
respondents  represented  an  effective response rate of 59%. The questionnaire was 
accompanied by a covering letter to the GP and a pre-paid envelope in which to return 
it; no incentive was given to GPs to complete the survey. In terms of gender, age and, 
type and location of practice this sample closely resembled national distributions [9, 
10]. Sixty-four percent of respondents were male and 10% worked in single-handed 
practices. The age distribution was as follows: <30 = 1%, 30-39 = 26%, 40-49 = 42%, 
50-59 = 27% and >60 = 5%.
GPs were asked to recall the number of requests they had received from patients for 
NRT and bupropion over the past month, and the number of prescriptions they had 
issued. They were further asked whether they thought bupropion and NRT should be 
available on NHS prescription; and whether they thought these medications should only 
be available if accompanied by behavioural support or counselling. The responses to 
these statements were recoded to either “yes” or “no” and “don’t know”. A number of attitude statements relating to smoking cessation and to NRT and Zyban were also 
presented to GPs requesting that they respond on a five-point Likert scale: strongly 
disagree, disagree, neutral, agree and strongly agree; although for reporting purposes 
they have been collapsed to disagree, neutral and agree (see Table 1).
Results
The mean number of requests made to GPs for NRT in the previous month was 4.3 
(median  =  3,  range:  0-80,  SD  [standard  deviation]  =  5.82).  The  mean  number  of 
prescriptions  issued  was  3.5  (0-40,  SD  =  4.63);  this  equated  to  80%  of  requests. 
Eleven percent (n = 72) of GPs reported having not received any requests for NRT in the 
previous month and 15% (n = 99) reported not issuing any prescriptions for NRT.
The mean number of requests made to GPs for bupropion in the previous month was 
1.9 (median = 1, range: 0-30, SD = 3.09). The mean number of prescriptions issued 
was 1.2 (0-15, SD = 2.07); this equated to 59% of requests. Over one-third (37%, n = 
72) of GPs reported having not received any requests for bupropion in the past month; 
nearly half (49%, n = 317) reported not issuing any prescriptions for bupropion during 
the same period. 
Ninety-five percent (n = 540) of GPs thought that NRT should be available on NHS 
prescription; 71% (n = 404) thought that it should only be available with behavioural 
support.  A  similar  proportion  (97%,  n  =  550)  thought  that  bupropion  should  be 
available on NHS prescription with 80% (n = 453) believing that it should only be 
available with behavioural support. Attitudes to NRT and bupropion were mostly positive (Table 1) although a substantial 
majority were concerned about the side effects of bupropion.
TABLE 1 NEAR HERE.
Eight  percent  (n  =  46)  of  GPs  who  received  requests  for  NRT  did  not  issue  any 
prescriptions at all. The demographic characteristics of these GPs were no different 
from those that did prescribe. When GPs’ responses to requests for NRT were coded to 
0 (any prescribing) and 1 (no prescribing) a forced entry logistic regression on to all the 
attitude items showed that GPs who did not issue any prescriptions were less likely to 
express the view that NRT should be available on the NHS (OR [odds ratio] = 0.55, p
<.03,  95%  CI  [confidence  interval]  0.33  - 0.91).  A  further  forced  entry  logistic 
regression of these responses (coded 1= ‘should be available’, 2= ‘should not’ or ‘don’t 
know’) with all the attitude items forced into the model simultaneously, showed that this 
in turn was positively related to whether GPs thought that: smokers should not have to 
pay for treatment themselves (OR = 2.43, p<.001, 95% CI 1.83 - 3.23 ), and negatively 
related to the view that NRT is not effective enough to make it worth the NHS paying 
for it (OR = 0.34, p<.001, 95% CI 0.25 - 0.48) and the low priority they would give 
NRT in the drug budget (OR = 0.35, p<.001, 95% CI 0.26 - 0.47). See Figure 1.
FIGURE 1 ABOUT HERE.
Twenty six percent (n = 102) of GPs who received a request for bupropion did not 
issue  any  prescriptions.  As  with  NRT  a  forced  entry  logistic  regression  with  all 
attitude items entered showed that it was GPs who did not accept that bupropion should be available on NHS prescription that were less likely to prescribe (OR = 0.66, 
p<.05, 95% CI 0.65 - 1.14); in addition, concern about side effects also played a 
significant role (OR = 1.46, P<.03, 95% CI 1.05 - 2.02). GPs’ views on whether 
bupropion should be available on NHS prescription were, as with NRT, in turn related 
to whether GPs thought that smokers should not have to pay for treatment themselves 
(OR = 2.08, p<.001, 95% CI 1.59 - 2.73),  and negatively related to the view that 
bupropion is not effective enough to make it worth the NHS paying for it (OR = 0.28, p
<.001, 95% CI 0.20 - 0.40) and the low priority they would give bupropion in the drug 
budget (OR = 0.47, p<.001, 95% CI 0.36 - 0.63). GPs who did not prescribe bupropion 
were 3.6 times more likely not to prescribe NRT (Chi-square = 24.7, Fishers exact p
<.001). See Figure 2.
FIGURE 2 ABOUT HERE.
Discussion
This survey found that GPs reported modest demand for stop-smoking medications, 
more for NRT than for bupropion. Their prescribing rate was less than the demand, 
more so for bupropion than NRT. The difference between the demand for NRT and 
bupropion and its supply was largely due to a minority of GPs who did not respond 
positively to any requests for prescriptions for these drugs. Not prescribing the stop-
smoking medications was linked to the view that they should not be available on NHS 
prescription, together in the case of bupropion with concern over side effects. It is 
possible that GPs did not respond positively to all requests for prescriptions because the  requests  came  from  patients  who  were  non-nicotine  dependent  or  who  were 
contra-indicated. However, very few smokers are contra-indicated for NRT and this 
would be unlikely to explain why some GPs did not prescribe at all.  
It is apparent that even in a healthcare system with strong technical guidance [6], 
widely  disseminated  national  guidelines  endorsed  by  professional  bodies  [7]  and 
government support there remains a proportion of GPs who have not accepted that 
stop-smoking medications are a legitimate item of NHS expenditure and are acting 
accordingly.  Although  internationally  there  is  still  debate  about  whether  smokers 
themselves should bear the cost of treatment to help them stop, in the UK the formal 
mechanism for addressing this issue is the National Institute of Clinical Excellence 
and this recognised that nicotine dependence is a disorder that merits treatment as 
would  any  other  disorder.  The  NHS  does  not  make  patients  pay  for  other  cost-
effective treatments, such as statins or anti-hypertensives, however much the patient 
may have contributed to his or her condition; there is no difference in this philosophy 
for patients who are nicotine dependent [6]. This suggests a continued need for GP 
education  so  that patients wishing to stop smoking are not disadvantaged through 
being denied access to medications to aid in their quit attempt. In addition, concerns 
over  bupropion’s  side-effects  are  leading  a  number  of  GPs  not  to  prescribe  this 
medication at all. Such a blanket refusal may not be in the interest of patients. Again, 
continued education is required to ensure that the advantages and disadvantages of 
bupropion to patients are assessed in a balanced fashion.
Although a Cochrane review [3] reported that the overall odds ratio for abstinence 
with  NRT  compared  with  placebo  was  maintained  regardless  of  the  intensity  of additional support, reservations have been voiced as to whether NRT and bupropion 
may be less effective without any such support [2]. This, together with the product 
labelling for bupropion, which states that it should be prescribed as an “adjunct to 
smoking  cessation  in  combination  with  motivational  support”  [11],  may  be 
responsible for the very high proportion of GPs who believed that NRT and bupropion 
should  only  be  available  with  behavioural  support.  The  existence  of  smoking 
cessation  services  to  provide  this  support,  which  combined  with  use  of 
pharmacotherapy further boost smokers’ chances of stopping smoking [7], may also 
have been a factor. 
This study was limited by the fact that it relied on self-report. However, the figures for 
prescriptions per GP match very closely the actual number of prescriptions issued at 
the time the survey was undertaken [12]. The response rate of 60% leaves scope for 
sample bias but the demographic characteristics of the sample were similar to the 
national population of GPs. Moreover, we found no evidence of differences between 
the GPs who responded using the first questionnaire and those who only responded 
after a reminder, suggesting that factors that inhibited responding were not related to 
our measures of interest. 
Finally treatment to aid smoking cessation in the UK is in a state of flux and the 
situation is likely to continue to change. Our survey is the most up-to-date information 
currently available and will hopefully serve as a benchmark against which to assess 
subsequent changes that might arise with the introduction of new policies.  Acknowledgements
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Submitted to Tobacco Control.Table 1: GPs’ responses to statements relating to smoking cessation and to the 
effectiveness and cost-effectiveness of NRT and bupropion
Disagree % (N)  Neutral % (N)
Agree % (N) 
NRT is not effective enough to make it worth the NHS paying for it 69 (440) 20 
(126) 11 (66)
Bupropion is not effective enough to make it worth the NHS paying for it 68 
(429) 21 (134) 11 (70)
I would give NRT a low priority in the drug budget 48 (300) 23 (148) 29 
(184)
I would give bupropion a low priority in the drug budget 42 (264) 28 (174) 31 
(193)
I think that bupropion is more effective than NRT 24 (155) 45 (280) 31 
(192)
I am concerned about side effects from bupropion 10 (66) 21 (130) 69 
(436)
Smokers should not have to pay for their stop smoking treatment themselves 41 
(259) 29 (182) 30 (187)
Stopping smoking is more a matter of willpower than anything else 32 (199) 19 
(121) 50 (312)
Note: Strongly disagree and disagree, and strongly agree and agree, collapsed in to single responsesFigure 1: Relationship between whether GPs respond to requests for NRT with a 
prescription and their attitudes towards NRT
Odds Ratio Odds Ratio
Smokers should not have to pay for their stop smoking treatment themselves
2.43
       
NRT is not effective enough to make it worth the NHS paying for it
0.34 NRT should be available on NHS prescription
0.55 Did not prescribe NRT
I would give NRT a low priority in the drug budget 0.35
  Figure 2: Relationship between whether GPs respond to requests for bupropion with a 
prescription and their attitudes towards bupropion
Odds Ratio Odds Ratio
Smokers should not have to pay for their stop smoking treatment themselves        
2.08
Bupropion is not effective enough to make it worth the NHS paying for it
0.28  Bupropion should be available on NHS prescription
0.66 Did not prescribe bupropion
I would give bupropion a low priority in the drug budget 0.47    
1.46
I am concerned about side effects from bupropion
  